Surmodics (SRDX)
(Delayed Data from NSDQ)
$32.37 USD
+0.15 (0.47%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $32.37 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SRDX 32.37 +0.15(0.47%)
Will SRDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SRDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRDX
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
SRDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates
ICU Medical (ICUI) Surpasses Q2 Earnings and Revenue Estimates
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates
Other News for SRDX
Technical picture remains unchanged for SRDX after it rises 0.99% on September 18
Technical picture remains unchanged for SRDX after it falls 0.05% on September 17
SRDX's price falls by 1.39% on September 16, though its technical setup remains stable.
The technical outlook for SRDX is unchanged after it rises 1.28% on September 15
Technical picture remains unchanged for SRDX after it falls 0.96% on September 12